FINWIRES · TerminalLIVE
FINWIRES

Nissan Signs MoU for UK Production of Chery Vehicles at Sunderland Plant

By

Nissan Motor (TYO:7201) and Chery Automobile's (HKG: 9973) Chery International UK have entered into a non-binding memorandum of understanding to explore having Nissan build Chery's passenger cars at the Sunderland facility in the UK under a contract manufacturing arrangement.

Under the proposed terms, Nissan would retain full ownership of the plant and employ all staff, with production of Chery vehicles potentially starting on Line One as early as fiscal year 2027, according to a statement on Wednesday.

The agreement follows Nissan's May decision to shift all its own manufacturing to Line Two as part of an effort to boost plant utilization.

While Nissan AMIEO Chairperson Massimiliano Messina called the move a significant step and pledged to pursue a mutually beneficial outcome, the MoU remains non-binding and both sides are continuing discussions without further public details at this time.

Related Articles

Asia

Optiscan Imaging Says Half of Target Patients Imaged in Human Breast Cancer Imaging Study

Optiscan Imaging (ASX:OIL) said 25 of the target 50 patients were imaged in its first in-human breast cancer imaging study at Royal Melbourne Hospital in Victoria, reaching a halfway mark milestone, according to a Thursday Australian bourse filing.The study is assessing surgical margins in breast cancer patients undergoing lumpectomy procedures using the InVue precision surgery imaging device for in vivo imaging and the InForm digital pathology imaging device for ex vivo imaging, per the filing.InVue is used intraoperatively in the resection cavity to generate live in vivo images immediately after tumor removal, while InForm is used to analyze the excised tissue.Clinical readouts of the analyzed cases to date show nine with clear margins, four with narrowly clear margins, and five with involved margins, the company said. There were no reported adverse events related to intravenous sodium fluorescein contrast agent injections.The study was expanded to a second clinical site to accelerate recruitment.

$ASX:OIL
Asia

IperionX Reports Net Present Value of $813 Million for US Critical Minerals Project in Definitive Feasibility Study

IperionX (ASX:IPX) said its definitive feasibility study for its Titan Critical Minerals Project in the US has returned an after-tax net present value of $813 million at an 8% discount rate, an after-tax internal rate of return of 39%, and an after-tax payback period of 3.6 years, according to a Thursday Australian bourse filing.The company said the study forecasts life-of-mine earnings before interest, taxes, depreciation and amortization (EBITDA) of $2.8 billion and after-tax free cash flow of $1.9 billion over an initial 14-year mine plan. The project is supported by a phase 1 development capital of $228.1 million and phase 2 incremental capital of $153.2 million, for total development capital of $381.3 million.Ore reserves stand at 117 million tons at 3.2% total heavy mineral (THM), containing 3.7 million tons of THM with about 80% classified as proved, the filing added.Phase 2 annual production is forecast at about 5,287 tonnes of heavy rare earth concentrate (HREC); 118,658 tonnes of ilmenite; 24,656 tonnes of rutile; and 65,668 tonnes of zircon concentrate, the filing said.The HREC contains strategically important heavy rare earths dysprosium, terbium and yttrium vital for US supply chains for high-performance magnets, defense, aerospace and semiconductor applications, it added.

$ASX:IPX
Asia

Aurobindo Pharma Inaugurates Biologics Contract Manufacturing Facility in Telangana, India

Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) on Wednesday inaugurated a biologics contract manufacturing facility of its subsidiary Theranym Biologics at Borapatla in Telangana, India, according to a same-day filing to the Indian stock exchanges.This marks Aurobindo's foray into biologics contract manufacturing.The company has roped in pharmaceutical company MSD as an anchor customer for the facility and will help to support the latter's supply chain in both domestic and export markets.

$BOM:524804$NSE:AUROPHARMA